Jade Biosciences, Inc. - Common Stock, $0.0001 par value per share (JBIO) Institutional Ownership

13F Institutional Holders and Ownership History from Q2 2025 to Q4 2025

Type / Class
Equity / Common Stock, $0.0001 par value per share
Symbol
JBIO on Nasdaq
Shares outstanding
49,428,467
Price per share
$13.86
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
15,474,903
Total reported value
$238,664,419
% of total 13F portfolios
0%
Share change
+793,386
Value change
+$37,240,094
Number of holders
58
Price from insider filings
$13.86
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Jade Biosciences, Inc. - Common Stock, $0.0001 par value per share (JBIO) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Fairmount Funds Management LLC 20% 0% $89,373,614 +$26,797,898 10,353,875 +43% Fairmount Funds Management LLC 06 Oct 2025
FMR LLC 15% $40,965,976 4,735,951 FMR LLC 30 May 2025
Venrock Healthcare Capital Partners III, L.P. 9.9% $32,654,542 3,220,369 Venrock Healthcare Capital Partners III, L.P. 28 Apr 2025
RA CAPITAL MANAGEMENT, L.P. 7% +72% $27,758,364 +$16,318,579 3,214,969 +143% RA Capital Management, L.P. 08 Oct 2025
BlackRock, Inc. 6.6% +26% $18,565,068 +$3,763,302 2,150,203 +25% BlackRock, Inc. 30 Sep 2025
VANGUARD GROUP INC 4.2% -23% $32,337,685 +$4,446,695 2,095,767 +16% The Vanguard Group 31 Dec 2025
Frazier Life Sciences Public Fund, L.P. 4.2% 0% $11,949,495 +$379,228 1,384,646 +3.3% Frazier Life Sciences Public Fund, L.P. 30 Sep 2025
TCG Crossover GP I, LLC 0.2% $649,193 64,023 TCG Crossover GP I, LLC 28 Apr 2025
Atlas Venture Fund XII, L.P. 0.2% $521,257 51,406 Atlas Venture Associates XII, L.P. 28 Apr 2025

As of 31 Dec 2025, 58 institutional investors reported holding 15,474,903 shares of Jade Biosciences, Inc. - Common Stock, $0.0001 par value per share (JBIO). This represents 31% of the company’s total 49,428,467 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Jade Biosciences, Inc. - Common Stock, $0.0001 par value per share (JBIO) together control 31% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 5.8% 2,870,313 +33% 0% $44,288,930
VANGUARD GROUP INC 4.2% 2,095,767 +21% 0% $32,337,685
Remedium Capital Partners, LLC 3.2% 1,577,750 0% 14% $24,345,000
Versant Venture Management, LLC 3.1% 1,525,820 0% 16% $23,543,403
Avidity Partners Management LP 2.8% 1,400,708 +24% 6.2% $21,612,924
MARSHALL WACE, LLP 1.8% 875,273 +2199% 0.01% $13,505,462
Aberdeen Group plc 1.8% 867,284 0.02% $13,382,192
GEODE CAPITAL MANAGEMENT, LLC 1.7% 841,808 +26% 0% $12,991,338
Soleus Capital Management, L.P. 1.6% 796,744 0% 0.52% $12,293,760
Affinity Asset Advisors, LLC 1.4% 714,956 +995% 0.79% $11,031,771
STATE STREET CORP 1.3% 642,921 +29% 0% $9,920,271
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.25% 125,772 +35% 0% $1,940,662
Nuveen, LLC 0.25% 124,545 +191% 0% $1,921,729
Bank of New York Mellon Corp 0.23% 114,906 +40% 0% $1,772,999
Sofinnova Investments, Inc. 0.22% 107,391 0% 0.07% $1,657,043
UBS Group AG 0.2% 96,786 +388% 0% $1,493,408
MORGAN STANLEY 0.16% 79,767 +47% 0% $1,230,805
BARCLAYS PLC 0.15% 72,194 +58% 0% $1,113,953
RENAISSANCE TECHNOLOGIES LLC 0.14% 69,601 0% $1,073,943
Connor, Clark & Lunn Investment Management Ltd. 0.14% 67,230 0% $1,037,359
GOLDMAN SACHS GROUP INC 0.13% 65,340 -60% 0% $1,008,196
WELLS FARGO & COMPANY/MN 0.1% 51,892 +109% 0% $800,693
RHUMBLINE ADVISERS 0.1% 50,053 +17% 0% $772,310
SCHRODER INVESTMENT MANAGEMENT GROUP 0.08% 39,279 0% $610,985
DEUTSCHE BANK AG\ 0.07% 34,455 +16% 0% $531,641

Institutional Holders of Jade Biosciences, Inc. - Common Stock, $0.0001 par value per share (JBIO) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 15,474,903 $238,664,419 +$37,240,094 $15.43 58
2025 Q3 31,617,300 $272,859,518 +$407,366 $8.63 74
2025 Q2 31,531,484 $315,000,764 +$314,968,047 $9.99 70